CJC-1295 w/DAC: The Long-Acting GHRH Analog and What Published Research Shows

Growth hormone-releasing hormone is produced in the arcuate nucleus of the hypothalamus and travels via the hypothalamic-pituitary portal system to the anterior pituitary. There it binds to GHRH receptors (GHRHR) on somatotroph cells - the pituitary cells that produce and store growth hormone.

GHRHR is a G-protein coupled receptor. Binding activates adenylyl cyclase, raising intracellular cAMP, which activates protein kinase A (PKA) and ultimately triggers exocytosis of GH from secretory granules. GHRH also stimulates GH gene transcription and somatotroph proliferation over longer timeframes.

Natural GHRH is released in pulses - typically 6-12 per 24 hours, with the largest pulse occurring 1-2 hours after sleep onset. Each pulse produces a transient GH surge. CJC-1295 with DAC maintains continuous GHRHR activation rather than pulsatile activation - an important distinction for interpreting research outcomes.

DAC (Drug Affinity Complex) is a proprietary modification that appends a reactive maleimide group to the C-terminus of the modified GHRH peptide (CJC-1295). Once injected, the maleimide reacts with the free thiol on cysteine-34 of circulating serum albumin, forming a stable thioether bond.

This binding is highly selective - albumin has one free cysteine and the maleimide reaction is specific to thiols. The result is a peptide-albumin conjugate that: - Blocks plasma proteases from accessing the peptide backbone - Prevents renal filtration (albumin is too large at ~66 kDa to be filtered) - Maintains biological activity at the GHRHR, since the albumin-bound peptide can still interact with pituitary receptors

The binding is reversible: as albumin turns over, free CJC-1295 is gradually released, creating a slow, sustained release profile. This pharmacokinetics model is the same mechanism exploited by fatty-acid-conjugated GLP-1 analogs like semaglutide.

The primary published human data for CJC-1295 with DAC comes from Teichman et al., 2006 (J Clin Endocrinol Metab). This was a Phase 1/2 dose-escalation study in healthy adults aged 21-61 across multiple dose cohorts (30, 60, 90, 120, and 180 mcg/kg), administered as both single injections and multiple weekly injections.

This trial established that a single GHRH analog injection could sustain measurable endocrine effects for 28 days - a pharmacological property that natural GHRH cannot achieve.

GH biology depends critically on the pattern of GH secretion, not just the total amount. Research in both animal models and humans has established that pulsatile GH release - discrete surges separated by low-GH troughs - produces different physiological effects than the same total GH delivered tonically (continuously).

Pulsatile GH: More anabolic, more effective at driving IGF-1 production in the liver, more consistent with normal physiological patterns. Natural GHRH pulses produce this pattern.

Tonic GH: Associated with receptor downregulation over time, different downstream signaling profiles, and less efficient IGF-1 generation per unit of GH.

CJC-1295 with DAC produces a tonic GHRHR signal - continuous stimulation of somatotrophs throughout the 6-8 day half-life. This means GH secretion from the pituitary becomes less pulsatile under CJC-1295 w/DAC compared to natural GHRH patterns. For research designs where preserving natural GH pulse architecture is important, shorter-acting GHRH analogs (like Tesamorelin or Modified GRF 1-29) provide more physiological activation patterns.

Tesamorelin is a GHRH analog with a trans-3-hexenoic acid modification that extends its half-life to ~30 minutes - short enough to preserve pulsatile GH release when dosed at meal times, long enough to resist plasma proteases. It is FDA-approved for HIV-associated lipodystrophy, making it the only GHRH analog with a confirmed therapeutic indication and robust human clinical trial database.

Modified GRF 1-29 (Mod-GRF, CJC-1295 without DAC) is the same amino acid sequence as CJC-1295 without the albumin-binding DAC modification. Half-life is roughly 30 minutes. It produces a single physiological GH pulse when injected and is typically dosed multiple times per day in research protocols.

CJC-1295 with DAC sits at the long half-life extreme - one or two weekly injections maintain continuous GHRHR activation. The tradeoff is the shift from pulsatile to tonic GH pattern. The choice between them depends on the research question: Tesamorelin or Mod-GRF for pulsatile research designs, CJC-1295 w/DAC for sustained IGF-1 elevation studies.

The GH secretagogue system has two distinct receptor pathways that converge on pituitary somatotrophs: - GHRHR pathway: Activated by GHRH and GHRH analogs (CJC-1295) - drives cAMP/PKA signaling - GHS-R1a pathway: Activated by ghrelin and ghrelin mimetics (Ipamorelin) - drives phospholipase C/calcium signaling

Both pathways independently trigger GH exocytosis, but when activated simultaneously they are synergistic - the combined GH pulse is larger than either pathway alone. This synergy is why CJC-1295 with DAC and Ipamorelin are almost always studied together in contemporary GH research protocols.

CJC-1295 with DAC provides the continuous background GHRHR activation (amplifying the amplitude ceiling of each GH pulse), while Ipamorelin provides pulsatile GHS-R1a activation (triggering the pulse event). Published synergy data from animal and human studies consistently shows that the combination produces 2-4x the GH release of either compound alone at equivalent doses.

Ipamorelin is preferred over older GH secretagogues (GHRP-6, GHRP-2) for this combination because of its selectivity - it does not co-stimulate cortisol or prolactin, keeping the hormonal profile clean.

CJC-1295 with DAC appears in the published literature across several research categories:

GH deficiency models: As a long-acting GHRH analog, CJC-1295 is studied as a potential alternative to daily GH injections for GH-deficient models, with the advantage of stimulating endogenous GH rather than replacing it exogenously. The pituitary's own GH secretion responds to the GHRHR signal, preserving feedback regulation.

Aging and IGF-1 decline: GH and IGF-1 both decline with age (somatopause). CJC-1295 is studied as a tool to restore GHRHR signaling in aging models, where the problem is reduced hypothalamic GHRH output rather than pituitary failure.

Body composition research: The 28-day sustained IGF-1 elevation profile from a single injection makes CJC-1295 w/DAC useful for research examining how sustained IGF-1 affects lean mass and adipose tissue in various models.

Pharmacokinetic studies: The albumin-binding mechanism itself is a research subject - CJC-1295 is used as a model compound to study how maleimide-albumin conjugation affects peptide pharmacokinetics, as this strategy is applicable to other short-lived therapeutic peptides.